Literature DB >> 18256682

Typical progression of myoclonic epilepsy of the Lafora type: a case report.

Pasquale Striano1, Federico Zara, Julie Turnbull, Jean-Marie Girard, Cameron A Ackerley, Mariarosaria Cervasio, Gaetano De Rosa, Maria Laura Del Basso-De Caro, Salvatore Striano, Berge A Minassian.   

Abstract

BACKGROUND: A 20-year-old woman presented to a specialist epilepsy center with a 3-year history of drug-resistant epileptic seizures, progressive myoclonus, ataxia, and cognitive decline. INVESTIGATIONS: Neurological examination, neuropsychological testing, electrophysiological studies, skin biopsy, MRI, genetic testing, and autopsy. DIAGNOSIS: Lafora disease (EPM2), resulting from a homozygous missense mutation in EPM2B (NHLRC1; c205C>G; Pro69Ala). MANAGEMENT: Symptomatic treatment with conventional antiepileptic and antimyoclonic drugs.

Entities:  

Mesh:

Year:  2008        PMID: 18256682     DOI: 10.1038/ncpneuro0706

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  19 in total

Review 1.  [Lafora disease: a review of the literature].

Authors:  L Desdentado; R Espert; P Sanz; J Tirapu-Ustarroz
Journal:  Rev Neurol       Date:  2019-01-16       Impact factor: 0.870

Review 2.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

Review 3.  Lafora disease.

Authors:  Julie Turnbull; Erica Tiberia; Pasquale Striano; Pierre Genton; Stirling Carpenter; Cameron A Ackerley; Berge A Minassian
Journal:  Epileptic Disord       Date:  2016-09-01       Impact factor: 1.819

Review 4.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 5.  Lafora disease: from genotype to phenotype.

Authors:  Rashmi Parihar; Anupama Rai; Subramaniam Ganesh
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

6.  Molecular dynamics simulations and principal component analysis on human laforin mutation W32G and W32G/K87A.

Authors:  P S Srikumar; K Rohini; Perumbilavil Kaithamanakallam Rajesh
Journal:  Protein J       Date:  2014-06       Impact factor: 2.371

7.  Trehalose Ameliorates Seizure Susceptibility in Lafora Disease Mouse Models by Suppressing Neuroinflammation and Endoplasmic Reticulum Stress.

Authors:  Priyanka Sinha; Bhupender Verma; Subramaniam Ganesh
Journal:  Mol Neurobiol       Date:  2020-10-22       Impact factor: 5.590

Review 8.  Emerging treatments for progressive myoclonus epilepsies.

Authors:  Antonella Riva; Alberto Guglielmo; Ganna Balagura; Francesca Marchese; Elisabetta Amadori; Michele Iacomino; Berge Arakel Minassian; Federico Zara; Pasquale Striano
Journal:  Expert Rev Neurother       Date:  2020-03-17       Impact factor: 4.618

9.  A novel EPM2A mutation yields a slow progression form of Lafora disease.

Authors:  Maria Adelaida Garcia-Gimeno; Pilar Natalia Rodilla-Ramirez; Rosa Viana; Xavier Salas-Puig; M Kathryn Brewer; Matthew S Gentry; Pascual Sanz
Journal:  Epilepsy Res       Date:  2018-07-21       Impact factor: 3.045

10.  Novel mutation in the NHLRC1 gene in a Malian family with a severe phenotype of Lafora disease.

Authors:  M Traoré; G Landouré; W Motley; M Sangaré; K Meilleur; S Coulibaly; S Traoré; B Niaré; F Mochel; A La Pean; A Vortmeyer; H Mani; K H Fischbeck
Journal:  Neurogenetics       Date:  2009-03-26       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.